Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.65 Average PT from Brokerages

Shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $3.70.

Several equities analysts have recently weighed in on the stock. Ascendiant Capital Markets upped their price objective on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the company a “buy” rating in a report on Monday. BTIG Research upped their price target on Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Friday, September 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Saturday, September 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Wednesday, August 13th. Finally, Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday.

Insider Buying and Selling at Lucid Diagnostics

In related news, Director Dennis Matheis purchased 100,000 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was acquired at an average price of $1.02 per share, for a total transaction of $102,000.00. Following the purchase, the director owned 665,443 shares of the company’s stock, valued at approximately $678,751.86. This trade represents a 17.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Luminus Management LLC lifted its stake in Lucid Diagnostics by 14.8% during the 3rd quarter. Luminus Management LLC now owns 912,805 shares of the company’s stock valued at $922,000 after acquiring an additional 117,975 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Lucid Diagnostics in the second quarter valued at about $43,000. Invesco Ltd. bought a new position in shares of Lucid Diagnostics during the second quarter valued at about $41,000. New York State Common Retirement Fund bought a new stake in Lucid Diagnostics in the 2nd quarter worth about $97,000. Finally, Quadrature Capital Ltd purchased a new stake in Lucid Diagnostics in the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Stock Down 1.0%

NASDAQ:LUCD opened at $1.03 on Tuesday. Lucid Diagnostics has a twelve month low of $0.75 and a twelve month high of $1.80. The company has a fifty day moving average of $1.08 and a 200-day moving average of $1.21. The firm has a market capitalization of $137.48 million, a P/E ratio of -0.87 and a beta of 1.19.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.